Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
Manzoli, L., Flacco, M., Boccia, S., D’andrea, E., Panic, N., Marzuillo, C., Siliquini, R., Ricciardi, G., Villari, P., Ioannidis, J., Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis, Abstract de <<8th European Public Health Conference>>, (Milano, 14-17 October 2015 ), <<EUROPEAN JOURNAL OF PUBLIC HEALTH>>, 2015; 25 (3): 74-74 [http://hdl.handle.net/10807/70743]
Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis
Me; Boccia;R; Ricciardi;
2015
Abstract
Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
